Conformationally restricted 3,4-diarylfuranones (2,3a,4,5-tetrahydronaphthofuranones) as selective cyclooxygenase-2 inhibitors.
暂无分享,去创建一个
M. Pal | Manojit Pal | Venugopal Rao Veeramaneni | Murali Nagabelli | Srinivas Rao Kalleda | Parimal Misra | Seshagiri Rao Casturi | Koteswar Rao Yeleswarapu | P. Misra | Venugopal Rao Veeramaneni | Murali Nagabelli | Srinivas Rao Kalleda | Seshagiri Rao Casturi | Koteswar Rao Yeleswarapu
[1] M. Pal,et al. A simple and rapid entry to 5-alkyl (aryl)-5-hydroxy-3,4-diarylfuranones and 3a-hydroxy-1-aryl-2,3a, 4,5-tetrahydronaphthofuranones via a tandem esterification and oxidative cyclization process , 2002 .
[2] D. Riendeau,et al. A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitors. , 1999, Bioorganic & medicinal chemistry letters.
[3] D. Riendeau,et al. SAR in the alkoxy lactone series: the discovery of DFP, a potent and orally active COX-2 inhibitor. , 1999, Bioorganic & medicinal chemistry letters.
[4] M. A. Rahim,et al. Isomeric acetoxy analogues of rofecoxib: a novel class of highly potent and selective cyclooxygenase-2 inhibitors. , 2002, Bioorganic & medicinal chemistry letters.
[5] R Gordon,et al. 2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors. , 1998, Bioorganic & medicinal chemistry letters.
[6] S. Higuchi,et al. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. , 1994, Prostaglandins.
[7] R. S. Rogers,et al. 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. , 2000, Journal of medicinal chemistry.
[8] J. Chow,et al. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2 , 1996, Nature Structural Biology.
[9] D. Riendeau,et al. Synthesis and biological evaluation of 5,6-diarylimidazo[2.1-b]thiazole as selective COX-2 inhibitors , 1997 .
[10] P. Lipsky,et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. , 1998, Arthritis and rheumatism.
[11] E. Knaus,et al. Design and synthesis of celecoxib and rofecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of sulfonamide and methylsulfonyl pharmacophores by an azido bioisostere. , 2001, Journal of medicinal chemistry.
[12] M. Pal,et al. ChemInform Abstract: Synthesis of 3,4-Diarylsubstituted Maleic Anhydride/Maleimide via Unusual Oxidative Cyclization of Phenacyl Ester/Amide. , 2002 .
[13] H Perrier,et al. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. , 1999, The Journal of pharmacology and experimental therapeutics.
[14] P. Prasit,et al. Synthesis and biological evaluation of 2,3-diarylthiophenes as selective Cox-2 and Cox-1 inhibitors , 1995 .
[15] N. Ackerman,et al. Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. , 1990, The Journal of pharmacology and experimental therapeutics.
[16] C. Koboldt,et al. Conformationally restricted 1,5-diarylpyrazoles are selective COX-2 inhibitors , 1996 .
[17] C. Koboldt,et al. 1,2-Diarylpyrroles as potent and selective inhibitors of cyclooxygenase-2. , 1997, Journal of medicinal chemistry.
[18] D. Bonnet-Delpon,et al. A SELECTIVE CONVERSION OF SULFIDE TO SULFOXIDE IN HEXAFLUORO-2-PROPANOL , 1998 .
[19] R. S. Rogers,et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). , 1997, Journal of medicinal chemistry.
[20] M. Percival,et al. The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. , 1999, Bioorganic & medicinal chemistry letters.
[21] C. Brideau,et al. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors , 1996, Inflammation Research.